Indomethacin may be beneficial for cough Alkotaji, which may not respond to other treatments.
Recent:Wang.
Submit updates/corrections .
Oct 3 |
Indomethacin for COVID-19: real-time meta analysis of 4 studies | |
| Statistically significant lower risk is seen for recovery. 2 studies (both from the same team) show statistically significant improvements. • Meta analysis using the most serious outcome reported shows 74% [-20‑94%] lower ris.. | ||
Aug 15 |
et al., iScience, doi:10.1016/j.isci.2023.107631 | Combating pan-coronavirus infection by indomethacin through simultaneously inhibiting viral replication and inflammatory response |
| In Vitro analysis of indomethacin for multiple human coronaviruses including SARS-CoV-2. Indomethacin exhibited antiviral activity against SARS-CoV-2 infection in human cell lines and lung airway organoid models. Treatment with indomethac.. | ||
Mar 31 |
et al., Master's Dissertation | Analysis of the effects of indomethacin on SARS-CoV-2 infection and the inflammatory response associated with the purinergic system |
| Vero E6 and Calu-3 In Vitro study showing that indomethacin protects against SARS-CoV-2-induced cytopathic effects and suppresses ATP-associated inflammatory responses. | ||
Jun 30 2022 |
et al., Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105788 | In-silico screening and in-vitro assay show the antiviral effect of Indomethacin against SARS-CoV-2 |
| In Silico study predicting indomethacin and vitamin A can bind critical host and viral proteins for SARS-CoV-2 interaction, and may be able to compensate for gene expressions changes related to SARS-CoV-2. | ||
Apr 19 2022 |
et al., Scientific Reports, doi:10.1038/s41598-022-10370-1 | An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients |
| 30% improved recovery (p=0.002), 98% lower progression (p<0.0001), and 17% improved viral clearance (p=0.19). RCT with 103 indomethacin and 107 paracetamol patients, showing lower progression and improved recovery with indomethacin. Notably, improvements include faster resolution of cough. [Alkotaji] previously hypothesised the benefit of indomet.. | ||
Jan 13 2022 |
et al., Immunopathologia Persa, doi:10.34172/ipp.2022.xx | Efficacy of oral indomethacin in the treatment of COVID-19 infection; a randomized clinical trial |
| 66% lower ventilation (p=1) and 40% slower recovery (p=0.52). Very small RCT with 22 indomethacin and 23 control patients, showing no significant difference in outcomes. All patients were treated with HCQ. | ||
Dec 8 2021 |
et al., Medical Science Monitor, doi:10.12659/MSM.935379 | Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis of Early COVID-19 and Treated at Home Within 3 Days or After 3 Days of Symptom Onset with Prescribed and Non-Prescribed Treatments Between November 2020 and August 2021 |
| Retrospective 158 COVID-19 patients in Italy treated with hesperidin, quercetin, indomethacin, aspirin, omeprazole, azithromycin, LMWH, and betamethasone (treatment specific for each patient), showing significantly lower hospitalization a.. | ||
Jul 31 2021 |
et al., J. Indian Med. Assoc., 119:7 | Use of indomethacin in COVID-19 patients: experience from two medical centres |
| 96% lower need for oxygen therapy (p<0.0001) and 43% faster recovery (p<0.0001). PSM retrospective 72 indomethacin and 72 paracetamol patients in India, showing lower progression and improved recovery with indomethacin. | ||
Apr 22 2021 |
et al., Current Pharmacology Reports, doi:10.1007/s40495-021-00257-6 | Indomethacin: Can It Counteract Bradykinin Effects in COVID-19 Patients? |
| Hypothesis that indomethacin will be beneficial for COVID-19 induced dry cough, via inhibition of the cyclooxygenase enzyme and reducing the level of inflammatory mediator bradykinin. | ||
Dec 4 2020 |
et al., Science, doi:10.1126/science.abe9403 | Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms |
| 67% lower hospitalization (p=0.34) and 57% lower progression (p=0.21). Analysis of interactions between viral and human proteins for SARS-CoV-2, SARS-CoV-1, and MERS-CoV and genetic screening to identify host factors that enhance or inhibit viral infection. Authors predict indomethacin will have antiviral ac.. | ||
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.